QuantuMDx Accelerates POCT Diagnostics with Rapid Multiplex PCR Solutions

MTEC UK

Overview

QuantuMDx is a medical technology company developing rapid multiplex PCR solutions and microarray technology for Point-of-Care Testing (POCT). The company aims to make diagnostic solutions for infectious diseases, antimicrobial resistance, and cancer accessible to all. Its Q-POC™ platform is a compact, rapid sample-to-answer multiplex PCR instrument that delivers results in approximately 30-35 minutes and has obtained CE Mark approval.

In Depth

Background: Evolution and Challenges of Molecular Diagnostics in POCT

The spread of infectious diseases and antimicrobial resistance (AMR) represents a global health challenge, making rapid and accurate diagnosis indispensable for effective management. Traditional molecular diagnostics often require large-scale laboratory equipment and specialized expertise, leading to lengthy turnaround times. The concept of Point-of-Care Testing (POCT) aims to resolve this by enabling rapid diagnosis at the patient’s bedside, but achieving laboratory-level multiplex PCR performance in a POCT device has been a significant technical hurdle.

Innovativeness of the QuantuMDx Q-POC™ Platform

QuantuMDx stands as a key innovator in the molecular diagnostics POCT field. The company has developed the Q-POC™ platform, which integrates rapid multiplex PCR solutions with microarray technology. The Q-POC™ is a compact, ‘sample-to-answer’ instrument capable of simultaneously detecting multiple pathogens and genetic markers in a short time, approximately 30-35 minutes, simply by loading a sample. This platform has obtained CE Mark approval, confirming its conformity and safety for the European market. This enables healthcare professionals to obtain rapid diagnostic results without complex laboratory procedures, thereby optimizing patient care.

Clinical Significance and Future Outlook

QuantuMDx’s technology aims to democratize access to diagnostic solutions across a wide range of fields, including infectious diseases, antimicrobial resistance, and cancer. Rapid multiplex POCT devices like the Q-POC™ improve healthcare access, especially in remote areas and resource-limited settings, and enhance the capacity to respond to public health crises. For instance, by simultaneously differentiating between influenza and COVID-19, it enables more precise treatment choices. In the future, this platform is expected to evolve further, expanding the range of detectable biomarkers and finding applications in advancing personalized medicine, particularly in fields such as precision oncology and drug susceptibility testing. QuantuMDx contributes to improving health outcomes for people worldwide through innovations in diagnostic technology.